LYINC 📈 Lyxor MSCI India UCITS Acc - Overview

Exchange: SW • Country: Switzerland • Currency: CHF • Type: Etf • ISIN: FR0010361683 • India Equity

LYINC: Equities, Indian, Stocks, Shares

‣ Company URL: http://www.amundietf.com ‣ Domicile: France ‣ Index Name: Morningstar India TME NR USD

Additional Sources for LYINC ETF

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

LYINC ETF Overview

Market Cap in USD 1,233m
Category India Equity
TER 0.85%
IPO / Inception 2006-11-07

LYINC ETF Ratings

Growth 5y 58.4%
Fundamental -
Dividend -
Rel. Strength Industry 469
Analysts -
Fair Price Momentum 27.25 CHF
Fair Price DCF -

LYINC Dividends

No Dividends Paid

LYINC Growth Ratios

Growth Correlation 3m -40.8%
Growth Correlation 12m 67.4%
Growth Correlation 5y 79.6%
CAGR 5y 9.07%
CAGR/Mean DD 5y 1.08
Sharpe Ratio 12m 0.74
Alpha -0.37
Beta 0.56
Volatility 20.28%
Current Volume 0k
Average Volume 20d 9.7k
What is the price of LYINC stocks?
As of December 27, 2024, the stock is trading at CHF 29.10 with a total of 0 shares traded.
Over the past week, the price has changed by -1.26%, over one month by -1.16%, over three months by -6.51% and over the past year by +17.20%.
Is Lyxor MSCI India UCITS Acc a good stock to buy?
Partly, yes. Based on ValueRay Analyses, Lyxor MSCI India UCITS Acc (SW:LYINC) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 58.44 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LYINC as of December 2024 is 27.25. This means that LYINC is currently overvalued and has a potential downside of -6.36%.
Is LYINC a buy, sell or hold?
Lyxor MSCI India UCITS Acc has no consensus analysts rating.
What are the forecast for LYINC stock price target?
According to ValueRays Forecast Model, LYINC Lyxor MSCI India UCITS Acc will be worth about 29.9 in December 2025. The stock is currently trading at 29.10. This means that the stock has a potential upside of +2.68%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 29.9 2.7%